Pharma

Your Article Summary

See Latest Articles

Gilead Sciences Agrees to Acquire CV Therapeutics for $20.00 Per Share
Gilead, 03/13/09

Gilead Sciences, Inc. and CV Therapeutics, Inc. announced the signing of a definitive agreement pursuant to which Gilead will acquire CV Therapeutics for $20.00 per share in cash through a tender offer and second step merger. CV Therapeutics' Board of Directors has unanimously approved the transaction and has agreed to recommend to its stockholders that they tender their shares pursuant to the tender offer. CV Therapeutics will become a wholly-owned subsidiary of Gilead. The transaction is valued at approximately $1.4 billion and is expected to be dilutive to Gilead's earnings in 2009, neutral to accretive in 2010 and accretive in 2011 and beyond.

Today in Marketing/Media/ROI...keeping you current

Receive free subspecialty "5-minute updates" via email

Visanne cleared for market launch in Europe as new treatment option for endometriosis
BayNews International, 12/08/09

Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer
Bristol Myers-Squibb Company, 12/07/09

Prodesses ProParaflu+(TM) Assay Cleared for US Marketing by FDA
Gen-Probe, 12/03/09

 See all of Marketing/Media/ROI